Overview


According to FutureWise analysis the market for heart failure drugs in 2023 is US$ 8.01 billion, and is expected to reach US$ 25.86 billion by 2031 at a CAGR of 15.78%.

Cardiac failure is a complicated clinical condition marked by unique signs and symptoms brought on by structural and functional heart problems. This syndrome is treated with angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Heart failure drugs, such as ACE inhibitors, which prevent the formation of angiotensin, which causes blood vessels to constrict, angiotensin, which helps to reduce the effect of angiotensin on the heart, and beta blockers, which block the actions of certain chemicals, work in a variety of ways in the case of a heart attack. The market for heart failure medications is being driven by an increase in the number of cardiovascular illnesses among people and a growing elderly population around the world.

The market for heart failure pharmaceuticals is growing due to an increase in demand for these drugs as they cure various symptoms of the condition and patients' reliance on them. Heart difficulties are being caused by changes in lifestyle, such as excessive alcohol consumption, smoking, and unhealthy diet habits, which is driving the demand for heart failure medications. The heart failure medications market is influenced by key companies' increased expenditure and the increased number of research and development activities. Furthermore, a growth in the prevalence of cardiac disorders as a result of obesity and a lack of physical activity boosts the market for heart failure drugs.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Heart Failure Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Heart Failure Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Novartis AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • CYTOKINETICS, INC. Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cardurion Pharmaceuticals
  • Cardior Pharmaceuticals
  • Actelion Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH.
  • Bristol-Myers Squibb Company
  • CYTOKINETICS, INC.
  • Eli Lilly and Company
  • Merck Sharp and Dohme Corp.
  • Quantum Genomics
  • RENOVA
  • SERVIER LABORATORIES
  • Stealth BioTherapeutics Inc.
  • Sanofi
  • Mylan N.V.
  • Bausch Health Companies Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Others

By Application

  • Injection
  • Capsule
  • Tablets

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User

  • Hospitals
  • Specialty Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Heart Failure Drugs Market By Type, By Application, By Distribution Channel, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Heart Failure Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Heart Failure Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Heart Failure Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Heart Failure Drugs Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. ACE Inhibitors
        2. Angiotensin Receptor Blockers
        3. Beta Blockers
        4. Diuretics
        5. Others

  • 8.   Heart Failure Drugs Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Capsule
        3. Tablets

  • 9.   Heart Failure Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 10.   Heart Failure Drugs Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Centers
        3. Others

  • 11.   North America Heart Failure Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Heart Failure Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Heart Failure Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Heart Failure Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •     1. Amgen Inc.
              1.1. Company Overview
              1.2. Product Portfolio
              1.3. SWOT Analysis
              1.4. Financial Overview
              1.5. Strategic Overview
          2. AstraZeneca
              2.1. Company Overview
              2.2. Product Portfolio
              2.3. SWOT Analysis
              2.4. Financial Overview
              2.5. Strategic Overview
          3. Bayer AG
              3.1. Company Overview
              3.2. Product Portfolio
              3.3. SWOT Analysis
              3.4. Financial Overview
              3.5. Strategic Overview
          4. Novartis AG
              4.1. Company Overview
              4.2. Product Portfolio
              4.3. SWOT Analysis
              4.4. Financial Overview
              4.5. Strategic Overview
          5. Gilead Sciences, Inc.
              5.1. Company Overview
              5.2. Product Portfolio
              5.3. SWOT Analysis
              5.4. Financial Overview
              5.5. Strategic Overview
          6. GlaxoSmithKline plc.
              6.1. Company Overview
              6.2. Product Portfolio
              6.3. SWOT Analysis
              6.4. Financial Overview
              6.5. Strategic Overview
          7. CYTOKINETICS, INC. Inc.
              7.1. Company Overview
              7.2. Product Portfolio
              7.3. SWOT Analysis
              7.4. Financial Overview
              7.5. Strategic Overview
          8. Teva Pharmaceutical Industries Ltd.
              8.1. Company Overview
              8.2. Product Portfolio
              8.3. SWOT Analysis
              8.4. Financial Overview
              8.5. Strategic Overview
          9. Cardurion Pharmaceuticals
              9.1. Company Overview
              9.2. Product Portfolio
              9.3. SWOT Analysis
              9.4. Financial Overview
              9.5. Strategic Overview
          10. Cardior Pharmaceuticals
              10.1. Company Overview
              10.2. Product Portfolio
              10.3. SWOT Analysis
              10.4. Financial Overview
              10.5. Strategic Overview
          11. Actelion Pharmaceuticals Ltd.
              11.1. Company Overview
              11.2. Product Portfolio
              11.3. SWOT Analysis
              11.4. Financial Overview
              11.5. Strategic Overview
          12. Boehringer Ingelheim International GmbH.
              12.1. Company Overview
              12.2. Product Portfolio
              12.3. SWOT Analysis
              12.4. Financial Overview
              12.5. Strategic Overview
          13. Bristol-Myers Squibb Company
              13.1. Company Overview
              13.2. Product Portfolio
              13.3. SWOT Analysis
              13.4. Financial Overview
              13.5. Strategic Overview
          14. CYTOKINETICS, INC.
              14.1. Company Overview
              14.2. Product Portfolio
              14.3. SWOT Analysis
              14.4. Financial Overview
              14.5. Strategic Overview
          15. Eli Lilly and Company
              15.1. Company Overview
              15.2. Product Portfolio
              15.3. SWOT Analysis
              15.4. Financial Overview
              15.5. Strategic Overview
          16. Merck Sharp & Dohme Corp.
              16.1. Company Overview
              16.2. Product Portfolio
              16.3. SWOT Analysis
              16.4. Financial Overview
              16.5. Strategic Overview
          17. Quantum Genomics
              17.1. Company Overview
              17.2. Product Portfolio
              17.3. SWOT Analysis
              17.4. Financial Overview
              17.5. Strategic Overview
          18. RENOVA
              18.1. Company Overview
              18.2. Product Portfolio
              18.3. SWOT Analysis
              18.4. Financial Overview
              18.5. Strategic Overview
          19. SERVIER LABORATORIES
              19.1. Company Overview
              19.2. Product Portfolio
              19.3. SWOT Analysis
              19.4. Financial Overview
              19.5. Strategic Overview
          20. Stealth BioTherapeutics Inc.
              20.1. Company Overview
              20.2. Product Portfolio
              20.3. SWOT Analysis
              20.4. Financial Overview
              20.5. Strategic Overview
          21. Sanofi
              21.1. Company Overview
              21.2. Product Portfolio
              21.3. SWOT Analysis
              21.4. Financial Overview
              21.5. Strategic Overview
          22. Mylan N.V.
              22.1. Company Overview
              22.2. Product Portfolio
              22.3. SWOT Analysis
              22.4. Financial Overview
              22.5. Strategic Overview
          23. Bausch Health Companies Inc.
              23.1. Company Overview
              23.2. Product Portfolio
              23.3. SWOT Analysis
              23.4. Financial Overview
              23.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients